Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

- Updates guidance regarding strategic transaction process

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced results from its bioequivalence study of ANX-514 (docetaxel emulsion). ANX-514 was determined to have comparable overall safety as Taxotere(R), the reference product, with no differences between treatment groups in severe toxicities. However, pharmacokinetic equivalence, the primary endpoint of the study, was not demonstrated based on benchmark regulatory standards.

"Following discussions with clinicians and experts in taxane pharmacokinetics, we believe that the increased blood-levels of docetaxel, which we observed solely during the first hour of a 168-hour observation period, do not affect the safety or efficacy of the drug and are not clinically relevant, and that our pharmacokinetic data should be sufficient to support an NDA for ANX-514," said Brian M. Culley, Chief Business Officer of ADVENTRX. "In addition, we have not fully investigated whether variability with respect to study drug administration and/or blood sample collection may have affected the results. However, the FDA is the final arbiter of safety and efficacy and, following discussion with the Agency, we will have more insight into whether additional pre-clinical and/or clinical activities may be necessary before submitting an NDA for ANX-514."

"The possibility of additional activities creates uncertainty around the cost and timeline to FDA approval of ANX-514, which may adversely impact our on-going strategic transaction discussions," Mr. Culley continued. "Consequently, and in light of our current working capital, we are evaluating both our strategic and non-strategic options."

The study data revealed higher blood-levels of docetaxel during and immediate
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... of Dental Experts to Advance the , Art, ... April 22 Milestone Scientific Inc. (OTC Bulletin ... technologies, today announced that the Company will be ... Anesthetic Delivery (C-CLAD) in Amelia Island, Florida. ...
... Delaying Retirement SAN MATEO, Calif., April 22 According ... approximately forty-five percent of adult children who are caring ... with two-thirds more concerned about their parents, financial situation ... one of many garnered from a new research study ...
... by UHC and Novation for Outstanding Service-NAPERVILLE, Ill., April ... the healthcare industry,s leading contracting services company, announced ... OMX ), a leader in office products ... Service Excellence Supplier Award most notably as Supplier of ...
... a national team of researchers led by Mayo Clinic ... associated with a significantly lower colorectal cancer risk. However, ... unclear. , The study, being presented at the AACR ... possible links between estrogen exposure and colon cancer molecular ...
... study, led by Lucy Selman and colleagues from King,s ... diseases and their family carers in sub-Saharan Africa often ... and its management, which impacts negatively on their ability ... have been published online by the BMJ ...
... Promoting Health and Wellness and Reducing Common and Costly ... Group Says to Senate and House LeadershipWASHINGTON, April 22 ... Fight Chronic Disease (PFCD) - an organization representing some ... today called on leaders in Congress to encourage updates ...
Cached Medicine News:Health News:Milestone Scientific Hosts Second Annual Symposium on Computer-Controlled Local Anesthetic Delivery (C-CLAD) 2Health News:Milestone Scientific Hosts Second Annual Symposium on Computer-Controlled Local Anesthetic Delivery (C-CLAD) 3Health News:After the Crash, Forty-Five Percent of Caring.com Visitors are Providing Financial Support to Aging Parents 2Health News:After the Crash, Forty-Five Percent of Caring.com Visitors are Providing Financial Support to Aging Parents 3Health News:OfficeMax Named the 2009 Recipient of The UHC Service Excellence Supplier Award 2Health News:OfficeMax Named the 2009 Recipient of The UHC Service Excellence Supplier Award 3Health News:Hormone therapy offers potential protective effect against colon cancer in older women 2Health News:Palliative care skills training needed for health-care staff in sub-Saharan Africa 2Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 2Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 3Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 4Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 5Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 6Health News:Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals 7
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
Medicine Products: